HealthcarePharmaceuticals & BiotechnologyPharmaceuticals

Pfizer Ltd

Showing the latest 10 filings. Sign in to filter or browse the full history.
10 of 30 filings·Updated 2 Oct 2026
Showing 10 of 30 filings.
2 Oct 20261 filing
Company UpdateNewspaper Publication

Please find enclosed copy of newspaper advertisements for Transfer and Dematerialisation of Physical Securities.

No brief for this announcement.Newspaper publications aren’t summarised. View the original using the link below
Filed 18:46View Source
29 Sept 20262 filings
Insider Trading / SASTClosure of Trading Window

Pfizer Ltd trading window closed from September 30, 2026 for half year ended September 30, 2026; reopen 48 hours after financial results are made public.

Pfizer Ltd trading window closed from September 30, 2026 for half year ended September 30, 2026; reopen 48 hours after financial results are made public.

Filed 16:54View Source
Company UpdateAction(s) initiated or orders passed

Pfizer Limited receives transfer pricing penalty order; plans appeal.

Filing Status

  • Order dated 25 Sep 2026 under Section 271G levies Rs 1,26,34,050 penalty.
  • Company to appeal; no material impact on finances or operations.
Filed 13:03View Source
18 Sept 20263 filings
Company UpdateChange in Directorate

Pfizer Limited has informed the Exchange about Resignation of Director/KMP/SMP

No brief for this announcement.This type of announcement aren’t summarised. View the original using the link below
Filed 16:54View Source
Company UpdateChange in Directorate

Pfizer Limited has informed the Exchange about Resignation of Director/KMP/SMP

No brief for this announcement.This type of announcement aren’t summarised. View the original using the link below
Filed 16:52View Source
Company UpdateChange in Management

Pfizer Limited Senior Director Sharad Goswami resigns to pursue opportunities outside Pfizer, effective Sept 25, 2026

Resignation of Senior Director, Policy & Public Affairs

  • Sharad Goswami resigns as Senior Director, Policy & Public Affairs, Sept 25, 2026 to pursue opportunities outside Pfizer.
Filed 16:26View Source
7 Sept 20261 filing
Board MeetingOutcome of Board Meeting

Pfizer Limited discontinues Minipress XL from Sept 7, 2026; to receive USD 13.9 million from Pfizer Inc.

Discontinuation and related payment

  • Discontinue Minipress XL marketing, distribution and sale with effect Sept 7, 2026
  • Reason: Pfizer Inc USA discontinued manufacture of Minipress XL
  • Receive lump sum payment of USD 13.9 million (~₹131.38 crore) from Pfizer Inc USA
Filed 11:25View Source
28 Jul 20262 filings
AGM/EGMAGM

Pfizer Limited's 75th AGM held via VC; dividend proposed; key resolutions tabled (outcome pending).

AGM Details

  • AGM held on July 28, 2026 at 3:00 p.m. IST via VC/OAVM, concluded 5:17 p.m.
  • Chair: Pradip Shah chaired from the registered office.
  • Meeting conducted through VC/OAVM per MCA/SEBI circulars.
  • Remote e-voting facility provided; Scrutinizer appointed for e-voting.

Key Resolutions

  • Adopt Audited Financial Statements for the year ended March 31, 2026.
  • Re-appoint P. Rengan as Director liable to retire by rotation.
  • Ratify remuneration payable to Kishore Bhatia & Associates, Cost Accountants, for FY 2027.

Dividend

  • Dividend of Rs 75 per equity share proposed under Ordinary Resolution.

Voting Results

  • Voting results to be declared within 2 working days after the meeting.
Filed 19:03View Source
Board MeetingOutcome of Board Meeting

Pfizer Limited approves unaudited Q1FY2026-27 results for quarter ended 30 June 2026

Financial results approved

  • Unaudited standalone Q1 FY2026-27 results approved: total income Rs 698.01 crore, net profit Rs 204.47 crore.

Regulatory and audit updates

  • Limited Review Report on the quarter ended 30 June 2026 issued; no modifications.
  • Audit Committee reviewed results prior to Board approval.

Key disclosures

  • Board approved results on 28 July 2026.
  • Single Pharmaceuticals segment; no additional segment disclosure.
  • Exceptional items for year ended 31 Mar 2026: ₹49.16 crore, severance under Cipla deal.
  • Labour Code changes increased employee benefit provisions by ₹7.43 crore for year ended 31 Mar 2026.
  • No subsidiaries/associates/joint ventures as of 30 Jun 2026.
Filed 13:52View Source
27 Jul 20261 filing
Company UpdateChange in Directorate

Pfizer Limited: Amit Agarwal resigns as Executive Director - Finance & CFO effective Oct 8, 2026

Resignation and Board Exit

  • Amit Agarwal resigns as ED - Finance & CFO to pursue an external opportunity, effective Oct 8, 2026.
  • Cease to be Director on the Board from Oct 8, 2026.
  • Relinquish CSR, Risk Mgmt, Admin & Share Transfer Committee memberships effective Oct 8, 2026.
Filed 16:32View Source
Showing 10 of 30 filings